Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn’s disease under infliximab therapy

Table 3 Predictive value of indicators on endoscopic relapse

	Youden index	Sensitivity	Specificity	Positive predictive value	Negative predictive value	Area under the ROC curve	P value
Predictors at week 14 of Endoscopic relapse at week 54
ITL ≤ 5.6 μg/mL	0.61 (0.41-0.72)	0.92 (0.75-0.99)	0.69 (0.56-0.79)	0.53 (0.44-0.62)	0.96 (0.86-0.99)	0.83 (0.73-0.90)	< 0.001
FCP > 238 μg/g	0.64 (0.38-0.78)	0.73 (0.52-0.88)	0.91 (0.82-0.97)	0.76 (0.59-0.88)	0.90 (0.82-0.94)	0.82 (0.72-0.89)	< 0.001
ITL ≤ 5.6 μg/mL and FCP > 238 μg/g	0.63 (0.40-0.80)	0.69 (0.48-0.86)	0.94 (0.85-0.98)	0.82 (0.63-0.92)	0.89 (0.82-0.93)	0.82 (0.72-0.89)	< 0.001
ITL ≤ 5.6 μg/mL or FCP > 238 μg/g	0.62 (0.47-0.74)	0.96 (0.80-1.00)	0.66 (0.53-0.77)	0.52 (0.44-0.60)	0.98 (0.87-1.00)	0.81 (0.71-0.88)	< 0.001
Predictors at week 54 of Endoscopic relapse at week 108
ITL ≤ 2.1 μg/mL	0.68 (0.40-0.87)	0.75 (0.43-0.95)	0.93 (0.81-0.99)	0.75 (0.49-0.90)	0.93 (0.83-0.97)	0.85 (0.72-0.93)	< 0.001
CRP > 3.0 mg/dL	0.45 (0.20-0.68)	0.50 (0.21-0.79)	0.95 (0.84-0.99)	0.75 (0.41-0.93)	0.87 (0.79-0.92)	0.73 (0.60-0.84)	0.012
ITL ≤ 2.1 μg/mL and CRP > 3.0 mg/dL	0.33 (0.08-0.58)	0.33 (0.10-0.65)	1.00 (0.92-1.00)	1.00 (1.00-1.00)	0.84 (0.78-0.89)	0.67 (0.53-0.79)	0.019
ITL ≤ 2.1 μg/mL or CRP > 3.0 mg/dL	0.80 (0.50-0.93)	0.92 (0.62-1.00)	0.88 (0.74-0.96)	0.69 (0.49-0.84)	0.97 (0.85-1.00)	0.90 (0.79-0.96)	＜0.001

ITL: Infliximab trough level; FCP: Fecal calprotectin; CRP: C-reactive protein; ROC: Receiver operating characteristic.